Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-06-18

Discovering Gene-Drug Interactions in Breast Cancer With a Systematic and Genetically Tractable Model

Cel

Biomedical research has been very successful in finding the individual genes that are deregulated in cancer and it is estimated that ~2% of all genes can be classified as “cancer genes”. However, it has proven challenging to translate this genomics knowledge into effective treatments.
One complication is that cancer cells typically carry many molecular aberrations and every tumor displays a unique pattern. This heterogeneity complicates the application of drugs and biologicals as it often interferes with patient response. Thus, unraveling the complex interplay between cancer genes and drugs is of great importance for effective patient-stratified cancer therapy.
Besides playing a role in drug resistance, the molecular changes also result in cancer cells becoming uniquely dependent on certain gene products or pathways. These cancer “vulnerabilities” offer opportunities targeted therapies, including those based on oncogene addiction and synthetic lethality. Therefore, these concepts have attracted much interest as they can help bridge the gap between cancer genomics and effective treatments.

I propose to identify cancer vulnerabilities and drug resistance mechanisms in breast cancer by developing a genetically tractable model system. Designed to capture relevant constellations of genetic aberrations found in patients, it extends our recently developed, systematic screening platform. Combined with bioinformatics integration of cell line data, this will result in a unique and powerful approach.
I aim to identify functional interactions between breast cancer genes and experimental or approved drugs. Detailed characterization of gene-drug interactions will reveal their translational potential for targeting specific cancer vulnerabilities in patients, or as biomarkers. Together, this project aims to improve therapies in breast cancer by identifying patient cohorts that are most likely to benefit from a given drug and revealing novel cancer Achilles’ heels.

Zaproszenie do składania wniosków

ERC-2012-StG_20111109
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

ERC-SG - ERC Starting Grant

Instytucja przyjmująca

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
Wkład UE
€ 1 128 323,98
Adres
WELLINGTON SQUARE UNIVERSITY OFFICES
OX1 2JD Oxford
Zjednoczone Królestwo

Zobacz na mapie

Region
South East (England) Berkshire, Buckinghamshire and Oxfordshire Oxfordshire
Rodzaj działalności
Higher or Secondary Education Establishments
Kontakt administracyjny
Gill Wells (Ms.)
Kierownik naukowy
Sebastian Nijman (Dr.)
Linki
Koszt całkowity
Brak danych

Beneficjenci (2)